1160264-95-8

Basic information

• Product Name: 2-(4-chlorophenyl)-3-methylquinoline-4-carbonyl chloride
• Synonyms: 2-(4-chlorophenyl)-3-methylquinoline-4-carbonyl chloride;4-quinolinecarbonyl chloride, 2-(4-chlorophenyl)-3-methyl-
• CAS NO: 1160264-95-8
• Molecular Formula: C17H11Cl2NO
• Molecular Weight: 316.18134
• Mol File: 1160264-95-8.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 455.0±45.0 °C(Predicted)
• Appearance: /
• Density: 1.335±0.06 g/cm3(Predicted)
• PKA: 1.38±0.44(Predicted)
• CAS DataBase Reference: 2-(4-chlorophenyl)-3-methylquinoline-4-carbonyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-chlorophenyl)-3-methylquinoline-4-carbonyl chloride(1160264-95-8)
• EPA Substance Registry System: 2-(4-chlorophenyl)-3-methylquinoline-4-carbonyl chloride(1160264-95-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 1160264-95-8(Hazardous Substances Data)

Usage

Molecular weight

275.71 g/mol

Compound type

Carbonyl chloride derivative of quinoline

Potential properties

Bioactive properties

Uses

Synthesis of pharmaceuticals and agrochemicals, research and development

Reactivity

Reactive due to the presence of the carbonyl chloride functional group

Specific properties

The presence of the chlorophenyl and methyl groups on the quinoline ring may impart specific biological or chemical properties.

Upstream product

• 43071-47-2 2-(4-chloro-phenyl)-3-methyl-quinoline-4-carboxylic acid 

Relevant articles and documents

Discovery of GSK2193874: An Orally Active, Potent, and Selective Blocker of Transient Receptor Potential Vanilloid 4

Transient Receptor Potential Vanilloid 4 (TRPV4) is a member of the Transient Receptor Potential (TRP) superfamily of cation channels. TRPV4 is expressed in the vascular endothelium in the lung and regulates the integrity of the alveolar septal barrier. Increased pulmonary vascular pressure evokes TRPV4-dependent pulmonary edema, and therefore, inhibition of TRPV4 represents a novel approach for the treatment of pulmonary edema associated with conditions such as congestive heart failure. Herein we report the discovery of an orally active, potent, and selective TRPV4 blocker, 3-(1,4′-bipiperidin-1′-ylmethyl)-7-bromo-N-(1-phenylcyclopropyl)-2-[3-(trifluoromethyl)phenyl]-4-quinolinecarboxamide (GSK2193874, 28) after addressing an unexpected off-target cardiovascular liability observed from in vivo studies. GSK2193874 is a selective tool for elucidating TRPV4 biology both in vitro and in vivo.